Jakob Dupont
CIK 1553335 · EVP, Head of R&D · last filed 2026-08-20
Jakob Dupont is an EVP, Head of R&D who has filed 52 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for PYXS, was dated Aug 20, 2026. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $167.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GOSS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
800 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PYXS | Director | 38,741 | $1.69 | $65.5K | -$107.1K | 7 | 2026-08-20 |
| BOLT | Director | — | $6.59 | — | $0 | 5 | 2026-06-11 |
| ATRA | EVP, Head of R&D | 11,632 | $8.35 | $97.1K | -$573.0K | 15 | 2023-03-06 |
| Apexigen, Inc. (APGNW) Delisted | Director | — | $0.03 | — | $0 | 1 | 2022-10-03 |
| GOSS | Chief Medical Officer | 581 | $9.15 | $5.3K | -$631.5K | 3 | 2020-02-19 |
Recent Filings
52 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-20 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2026-07-02 | PYXS | Mixed | — | -$51.1K | EDGAR |
| 2026-06-30 | PYXS | Notice (144) | −35,000 | -$107.0K | EDGAR |
| 2026-06-11 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2026-03-25 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2025-12-16 | BOLT | Mixed | — | $0 | EDGAR |
| 2025-07-02 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2025-05-05 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2025-04-02 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2024-09-06 | BOLT | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.